Overview

Autologous Stem Cell Transplantation for Crohn's Disease

Status:
Recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the safety and effectiveness of administering high-dose chemotherapy followed by infusion of autologous CD34-selected peripheral blood stem cells (PBSC) in pediatric and adult patients with severe Crohn's disease.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Paul Szabolcs
Treatments:
Alemtuzumab
Antilymphocyte Serum
Cyclophosphamide
Melphalan
Rituximab
Thiotepa
Thymoglobulin